ACCESS Newswire
21 Nov 2022, 13:38 GMT+10
VANCOUVER, BC / ACCESSWIRE / November 21, 2022 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC:XPHYF)(FSE:4XT) is pleased to report on a successful CPHI pharma conference in Frankfurt, Germany, attended by the BioNxt team earlier this month ('CPHI'). CPHI is the largest pharma conference in the world and the 2022 exhibition was the first comprehensive in-person CPHI event since the start of the pandemic.
CPHI provides an opportunity for pharma professionals to meet premier suppliers and buyers, discover new pharma trends, learn about ground-breaking ideas and innovations, and hear from leading industry experts. It is the world's most important gathering for ingredients, machinery, equipment, technology, package and contract service suppliers, distributors and buyers from the pharma industry.
BioNxt carried out a number of important meetings at CPHI with potential contract manufacturers, products licensees, and new product collaborators. As BioNxt advances its lead drug formulation product, a Rotigotine transdermal patch for the treatment of Parkinson's disease, the Company is forging a path towards regulatory approval, commercial production and global distribution. CPHI provided an opportunity to connect and reconnect with several potential strategic parts of its commercial pathway.
BioNxt is continually exploring and reviewing new product opportunities to capitalize on its platform technologies for transdermal and oral dissolvable drug formulations. CPHI also provided an opportunity to follow-up and confirm a promising opportunity to develop a novel oral dissolvable application of an approved active pharmaceutical ingredient for the treatment of a major neurological disorder. We look forward to further announcements in this regard.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: [email protected]
Phone: +1 780-818-6422
Cautionary Statement Regarding 'Forward-Looking' Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as 'expects', 'intends', 'is expected', 'potential', 'suggests' or variations of such words or phrases, or statements that certain actions, events or results 'may', 'could', 'should', 'would', 'might' or 'will' be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
Get a daily dose of Irish Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Irish Sun.
More InformationDOHA, Qatar: Boeing secured its largest widebody aircraft deal this week, as Qatar Airways placed firm orders for 160 jets with options...
NEW YORK CITY, New York: Goldman Sachs has agreed to pay a US$1.45 million civil penalty to resolve allegations from the Financial...
WASHINGTON, D.C.: The largest firefighters' union in the United States is calling for federal antitrust authorities to investigate...
LOS ANGELES, California: One person died and 32 others were hurt when a tour bus and an SUV crashed on a freeway near Los Angeles over...
COLOMBO, Sri Lanka: A passenger bus carrying nearly 50 people skidded off a cliff in Sri Lanka's central highlands, killing 21 and...
WASHINGTON, D.C.: U.S. President Donald Trump signed an executive order this week to lower the cost of prescription drugs in the United...
STOCKHOLM, Sweden: Sweden plans to propose that the European Union join the Pacific Rim trading bloc, the CPTPP, aiming to create the...
DUBLIN, Ireland: Ford is set to release a software update within the next two weeks for 2,850 Irish owners of Kuga plug-in hybrid vehicles...
DUBLIN, Ireland: Ireland has the lowest availability rate for new cancer medicines in Western Europe, with patients waiting nearly...
WARSAW, Poland: Poland has ordered Russia to shut down its consulate in Krakow following allegations that Moscow was involved in a...
DUBLIN, Ireland: Hundreds of spectators gathered at the Hill of Uisneach over the weekend for a Celtic fire procession, a centuries-old...
DUBLIN, Ireland: With artificial intelligence rapidly reshaping industries worldwide, Ireland has established a new Oireachtas committee...